Phaseline

Companies › Calla Lily Clinical Care

Calla Lily Clinical Care: clinical trials, targets and expected readouts

1 active drug program in 22 registered trials: 11 Phase 4, 4 Phase 3, 4 Phase 2, 3 Phase 1; Genitourinary, Infectious disease, Metabolic and endocrine, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Progesterone
Progesterone receptor agonist
PGRPhase 1Luteal Phase Insuffiency; Luteal Support; Smoking; Pregnancy Related …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06102863ProgesteronePhase 2Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage IOncologyAug 2025
NCT05969795ProgesteronePhase 1Pregnancy RelatedGenitourinaryApr 2026
NCT06875752ProgesteronePhase 4Luteal SupportOtherDec 2026
NCT06875752ProgesteronePhase 4Luteal SupportOtherDec 2026
NCT07136922ProgesteronePhase 1Luteal Phase InsuffiencyOtherDec 2026
NCT07136922ProgesteronePhase 1Luteal Phase InsuffiencyOtherDec 2026
NCT06807580ProgesteronePhase 2Transgender WomenOtherFeb 2027
NCT06530459ProgesteronePhase 2ArthralgiaGenitourinaryApr 2027
NCT04783857ProgesteronePhase 4SmokingOtherJun 2027
NCT05899010ProgesteronePhase 3InfertilityGenitourinaryJun 2027
NCT05899010ProgesteronePhase 3InfertilityGenitourinaryJun 2027
NCT05080569ProgesteronePhase 4Pregnancy RelatedGenitourinaryJul 2027
NCT06856174ProgesteronePhase 4HIV InfectionInfectious diseaseSep 2027
NCT05586724ProgesteronePhase 3Menopausal SymptomsGenitourinaryDec 2027
NCT06610305ProgesteronePhase 4Major Depressive DisorderPsychiatryJun 2028
NCT06834594ProgesteronePhase 4Turner SyndromeMetabolic and endocrineJul 2028
NCT06834594ProgesteronePhase 4Turner SyndromeMetabolic and endocrineJul 2028
NCT07448597ProgesteronePhase 4PreeclampsiaOtherAug 2028
NCT05787509ProgesteronePhase 4Preterm BirthOtherApr 2029
NCT07508657ProgesteronePhase 4InfertilityGenitourinaryJun 2029
NCT07436793ProgesteronePhase 2Endometrial Endometrioid AdenocarcinomaOncologyJun 2030
NCT06851754ProgesteronePhase 3Premature Ovarian InsufficiencyMetabolic and endocrineDec 2031

Targets

PGR (1)

Companies with the same targets

Changchun GeneScience Pharmaceutical Insud Pharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.